Anthropic launches Claude Science for drug discovery, plans own drug development
Anthropic enters AI drug race with Claude Science and neglected disease focus.
At The Briefing: AI for Science event, Anthropic unveiled Claude Science, a new AI workbench designed to centralize scattered tools and datasets for researchers, while also generating figures and visuals. The company framed the launch as a way to dramatically accelerate scientific discovery and healthcare interventions, listing biotech and pharma customers already using Claude. More boldly, Anthropic's head of life sciences Eric Kauderer-Abrams announced that the company will itself develop drugs targeting neglected diseases, becoming one of the few frontier AI companies to pursue direct drug development alongside selling AI tools to other drugmakers.
Experts note the AI drug boom is still far from delivering approved treatments. Namshik Han, a Cambridge professor and CardiaTec cofounder, said AI is applied at every stage of drug discovery, from compound identification to clinical trials, but the term is broadly used. Matthew Todd, a UCL drug discovery professor, added that the field is a long way from regulatory approval for any AI-designed drug. Anthropic's lack of detail on specific diseases, lab partnerships, or clinical plans underscores the uncertainty surrounding AI-driven drug development efforts.
- Anthropic launched Claude Science, an AI workbench consolidating data and generating figures for scientists.
- Company plans to develop drugs for neglected diseases, directly competing with its own biotech customers.
- Experts say AI drug discovery is broad but far from approved drugs; Anthropic has not shared specifics on candidates or partnerships.
Why It Matters
Anthropic's signal that AI companies will evolve from tools to drug developers, reshaping pharma competition.